Pharmacokinetics of Full Length and Two-Domain Tissue Factor Pathway Inhibitor in Combination with Heparin in Rabbits

Summary

Tissue factor pathway inhibitor (TFPI) is a feed back inhibitor of the initial activation of the extrinsic pathway of coagulation. In humans, injection of heparin results in a 2-6 fold increase in plasma TFPI and recent studies suggest that TFPI may be important for the anticoagulant activity of heparin. Full length (FL) TFPI, but not recombinant two-domain (2D) TFPI, has a poly cationic C-terminus showing very strong heparin binding. Therefore, we have investigated if heparin affects the pharmacokinetics of TFPI with and without this C-terminus.

FL-TFPI (608 U/kg) and 2D-TFPI (337 U/kg) were injected intravenously in rabbits with and without simultaneous intravenous injections of low molecular weight heparin (450 anti-XaU/kg).

Heparin decreased the volume of distribution and the clearance of FL-TFPI by a factor 10-15, whereas the pharmacokinetics of 2D-TFPI were unaffected by heparin. When heparin was administered 2 h following TFPI the recovery of FL-TFPI was similar to that found in the group receiving the two compounds simultaneously, suggesting that the releasable pool of FL-TFPI is removed very slowly in the absence of circulating heparin.

• References

• 1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-10370
• 2 Rapaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemostas 1991; 66: 6-15
• 3 Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546
• 4 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein associated coagulation inhibitor. Nature 1989; 338: 518-520
• 5 Nordfang O, Bjørn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991; 30: 10371-10376
• 6 Wesselschmidt R, Likert K, Girard TJ, Wun TC, Broze GJ. Tissue factor pathway inhibitor. The carboxy terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-2009
• 7 Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ, Warren TG, Wun TC. Recombinant lipoprotein associated coagulation inhibitor inhibits tissue thromboplastin induced intravascular coagulation in the rabbit. Blood 1990; 76: 1538-1545
• 8 Holst J, Lindblad B, Bergqvist D, Østergaard P, Nordfang O. Is EPI an antithrombotic agent comparable to LMWH?. Thromb Heamostas 1991; 65: 951 (Abstr)
• 9 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813
• 10 Valentin S, Østergaard P, Kristensen H, Nordfang O. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays. Blood Coagul Fibrinol 1991; 2: 629-635
• 11 Wun TC. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulphated polysaccharides. Blood 1992; 79: 430-438
• 12 Valentin S, Østergaard P, Kristensen H, Nordfang O. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin. Blood Coagul Fibrinol 1992; 3: 221-222 (Letter)
• 13 Abildgaard U, Lindahl AK, Sandset PM. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Haemostasis 1991; 21: 254-257
• 14 Palmier MO, Hall LJ, Reisch CM, Baldwin MK, Wilson AGE, Wun TC. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemostas 1992; 68: 33-36
• 15 Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Møller KB, Meidal-Pedersen J, Bech TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor. J Biol Chem 1990; 265: 16796-16803
• 16 Petersen JGL, Meyn G, Rasmussen JS, Petersen J, Bjørn SE, Jonassen I, Christiansen L, Nordfang O. Characterization of human tissue factor pathway inhibitor (TFPI) variants expressed in saccharomyces cerevisiae. J Biol Chem. in press
• 17 Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor in plasma and plasma fractions. Thromb Res 1987; 47: 389-400
• 18 Teien AN, Lie M, Abildgaard U. Assay of heparins in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 549-553
• 19 Mätzsch T, Bergqvist D, Hedner U, Østergaard P. Effects of an enzymatically depolymerized heparin as compared to conventional heparin in healthy volunteers. Thromb Haemostas 1987; 57: 97-101
• 20 Olsson DM. A sequential simplex program for solving minimization problems. J Quality Tech 1974; 6: 53-57
• 21 Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharm Dyn 1981; 4: 879-885
• 22 Warn-Cramer B, Maki SL, Rapaport SI. Heparin releasable and platelet pools of tissue factor pathway inhibitor (TFPI) in rabbits. Blood 1991; 78: 220 (Abstr)
• 23 Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoprotein associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-18837
• 24 Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in postheparin plasma and in plasma from cancer patients. Blood Coagul Fibrinol 1991; 2: 713-721